View Clinical Trial (Medical Research Study)

Exercise or Relaxation for Smoking Cessation - NCT00921388-06030(Clinical Trial 297993)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Farmington
State:  
CT
Zip Code: 06030
Conditions: Nicotine Dependence - Smoking Cessation
Purpose: This research study is being done to find out if adding a moderate exercise program or a relaxation program to a smoking cessation treatment program will improve smoking cessation and health in postmenopausal women. We hope to learn which group is more successful at quitting, has less symptoms of withdrawal from smoking and has improved health.
Study summary: Prevalence of smoking among women has declined more slowly in women than among men. Women who quit smoking substantially reduce the risk of premature death. A multi-modal approach to smoking cessation with combined behavioral and pharmacological interventions generally yields the highest success rates. The majority of subjects who are able to achieve abstinence return to smoking. Smoking relapse rates are 50-80% within one year with the majority of smokers relapsing within the first 3 months. Interventions are needed to both enhance smoking cessation rates and prevent relapse rates in order to substantially impact long-term quit rates.We intend to compare the effectiveness of a smoking cessation program combined with a moderate exercise program to an identical smoking cessation program combined with a relaxation-meditation control condition.
Criteria: Inclusion Criteria: - Postmenopausal women at least 45 years of age - Smoking at least 10 cigarettes per day - Motivated to quit smoking - Ambulatory - Currently exercising for 90 minutes of moderate exercise or less per week - Motivated to exercise - Permission from Primary Care Provider - Good general health Exclusion Criteria: - Denied medical clearance from primary care provider - Unstable angina or uncompensated heart failure - Systolic blood pressure greater than 165 or diastolic blood pressure greater than 100 - Heart attack or stroke within the preceding 6 months - Hip fracture within the preceding 6 months - Unstable medical or psychiatric disorder (e.g., current major depressive disorder or substance abuse or dependence) - Exercise-exacerbated neuromuscular disorder - Treatment for depression within the last year - Estimated creatinine clearance of less than 30cc/minute - Current use of a smoking cessation aid (i.e., bupropion, NRT, clonidine) - Current use of psychotropic medication for a psychiatric problem - Prescription narcotic abuse or dependence with the exception of people that have been stabilized on Methadone Maintenance or Suboxone - Previous serious adverse event with Chantix use
Study is available at: University of Connecticut Health Center
Farmington, CT 06030
United States

Primary Contact:
Peter Krzykowski
Email: krzykowski@uchc.edu
Phone: 860-679-3136

Secondary Contact:
Peter Krzykowski, B.A.
Email: krzykowski@uchc.edu
Phone: 860-679-4219
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.